| 1. |
- De Ferrari, G. M., et al.
(author)
-
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure
- 2011
-
In: European heart journal. - : Oxford University Press (OUP). - 1522-9645 .- 0195-668X. ; 32:7, s. 847-855
-
Journal article (peer-reviewed)abstract
- AIMS: In chronic heart failure (CHF), reduced vagal activity correlates with increased mortality and acute decompensation. Experimentally, chronic vagus nerve stimulation (VNS) improved left ventricular (LV) function and survival; clinically, it is used for the treatment of drug-refractory epilepsy. We assessed safety and tolerability of chronic VNS in symptomatic CHF patients, using a novel implantable nerve stimulation system. The secondary goal was to obtain preliminary data on clinical efficacy. METHODS AND RESULTS: This multi-centre, open-label phase II, two-staged study (8-patient feasibility phase plus 24-patient safety and tolerability phase) enrolled 32 New York Heart Association (NYHA) class II-IV patients [age 56 +/- 11 years, LV ejection fraction (LVEF) 23 +/- 8%]. Right cervical VNS with CardioFit (BioControl Medical) implantable system started 2-4 weeks after implant, slowly raising intensity; patients were followed 3 and 6 months thereafter with optional 1-year follow-up. Overall, 26 serious adverse events (SAEs) occurred in 13 of 32 patients (40.6%), including three deaths and two clearly device-related AEs (post-operative pulmonary oedema, need of surgical revision). Expected non-serious device-related AEs (cough, dysphonia, and stimulation-related pain) occurred early but were reduced and disappeared after stimulation intensity adjustment. There were significant improvements (P < 0.001) in NYHA class quality of life, 6-minute walk test (from 411 +/- 76 to 471 +/- 111 m), LVEF (from 22 +/- 7 to 29 +/- 8%), and LV systolic volumes (P = 0.02). These improvements were maintained at 1 year. CONCLUSIONS: This open-label study shows that chronic VNS in CHF patients with severe systolic dysfunction may be safe and tolerable and may improve quality of life and LV function. A controlled clinical trial appears warranted.
|
|
| 2. |
- Barnes, PD, et al.
(author)
-
Antihyperon-hyperon production in the threshold region at LEAR
- 1996
-
In: PHYSICS OF ATOMIC NUCLEI. - : AMER INST PHYSICS. ; , s. 1460-1466
-
Conference paper (peer-reviewed)abstract
- The experiment PSI185 studies the antihyperon-hyperon production in antiproton-proton annihilation at LEAR/CERN up to 2 GeV/c. This is achieved by investigation of the channels (p) over bar p --> <(Lambda)over bar>Lambda, <(Lambda)over bar>Sigma(0) + c.c.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Paschke, K. D., et al.
(author)
-
Experimental determination of the complete spin structure for (p)over-barp ->(Lambda)over-bar Lambda at p((p)over-bar)=1.637 GeV/c
- 2006
-
In: Physical Review C. Nuclear Physics. - 0556-2813 .- 1089-490X. ; 74:1, s. 015206-
-
Journal article (peer-reviewed)abstract
- The reaction (p) over barp -> (Lambda) over bar Lambda -> (p) over bar pi(+)p pi(-) has been measured with high statistics at a beam momentum of p((p) over bar)=1.637GeV/c. The use of a transversely polarized frozen-spin target combined with the self-analyzing property of Lambda/(Lambda) over bar decay allows access to unprecedented information on the spin structure of the interaction. The most general spin-scattering matrix can be written in terms of 11 real parameters for each bin of scattering angle; each of these parameters is determined with reasonable precision. From these results, all conceivable spin correlations are determined with inherent self-consistency. Good agreement is found with the few previously existing measurements of spin observables in (p) over barp ->(Lambda) over bar Lambda near this energy. Existing theoretical models do not give good predictions for those spin observables that had not been previously measured.
|
|
| 6. |
|
|
